|Dr. Niels C. Riedemann M.D., Ph.D.||Co-Founder, CEO & Exec. Director||N/A||N/A||1972|
|Prof. Renfeng Guo||Co-Founder, Chief Scientific Officer & Exec. Director||N/A||N/A||1970|
|Mr. Arnd Christ||Chief Financial Officer||N/A||N/A||1966|
|Mr. Jason M. Marks J.D.||Chief Legal Officer, Gen. Counsel & Corp. Sec.||N/A||N/A||1976|
|Mr. Jordan Silverstein||Head of Corp. Devel. & Strategy||N/A||N/A||N/A|
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
InflaRx N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.